Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ULK1 | O75385 | 1/20 | 0.40 |
| ▸ | CCNK | O75909 | 14/20 | 0.39 |
| ▸ | CDK12 | Q9NYV4 | 14/20 | 0.39 |
| ▸ | CDK7 | P50613 | 5/20 | 0.39 |
| ▸ | CCNH | P51946 | 5/20 | 0.39 |
| ▸ | MNAT1 | P51948 | 5/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 11/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 11/20 | 0.38 |
| ▸ | CDK2 | P24941 | 11/20 | 0.38 |
| ▸ | CDK9 | P50750 | 11/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.38 |
| ▸ | CLK2 | P49760 | 1/20 | 0.38 |
| ▸ | CLK3 | P49761 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30348299 | 1.00 | ULK1 (0.40) | ULK1CCNKCDK12CDK7CCNH | |
| SCHEMBL25544873 | 0.91 | RET (0.38) | ULK1CCNKCDK12CDK7CCNH | |
| SCHEMBL30348779 | 0.90 | DYRK1A (0.49) | ULK1CCNKCDK12CDK7CCNH | |
| SCHEMBL25520274 | 0.90 | DYRK1A (0.49) | ULK1CCNKCDK12CDK7CCNH | |
| SCHEMBL25519918 | 0.88 | RET (0.51) | ULK1RETDYRK1ACLK2CLK3 | |
| SCHEMBL30405737 | 0.88 | RET (0.51) | ULK1RETDYRK1ACLK2CLK3 | |
| SCHEMBL25265742 | 0.86 | TDO2 (0.47) | CCNKCDK12CDK7CCNHMNAT1 | |
| SCHEMBL25200864 | 0.86 | TDO2 (0.47) | CCNKCDK12CDK7CCNHMNAT1 | |
| SCHEMBL30406803 | 0.86 | TDO2 (0.47) | CCNKCDK12CDK7CCNHMNAT1 | |
| SCHEMBL30347165 | 0.86 | RET (0.41) | CCNKCDK12CDK7CCNHMNAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167133-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2023-06-01 | — | — | US | disclosed |
| US-20230167133-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167133-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF | DYRK1A, DYRK1B, DYRK2 | ULK1 266/4885CCNK 44/4885CDK12 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.